Rezera files for IPO to fund NLRP3 peripheral artery disease program

Rezera, which rebranded from NodThera earlier this year, has entered the queue for an initial public offering.

The filing, submitted on Wednesday, is intended to raise capital to support the company’s decade-long work on NLRP3-targeted therapies for peripheral artery disease.

The IPO proceeds are expected to bolster research and development efforts as the biotech advances its pipeline in this therapeutic area.

The move reflects Rezera’s strategy to secure funding for its ongoing programs and expand its presence in the cardiovascular market.